FeMike
2 minutes ago
Your position demonstrates a failure to recognize the potential monetary value for a new cancer treating paradigm, post initial marketing license and hence proof of concept, that is at once safe, efficacious, easily combined and enhanced with checkpoint inhibitors, csf1r, poly-iclc and other adjuvan